Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.69 -1.38 (-3.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,235,207
Open 35.34
Bid (Size) 34.28 (2)
Ask (Size) 34.80 (5)
Prev. Close 36.07
Today's Range 34.30 - 35.66
52wk Range 19.20 - 36.97
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Via Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga

Performance

YTD
+44.96%
+44.96%
1 Month
+0.49%
+0.49%
3 Month
+25.69%
+25.69%
6 Month
+60.90%
+60.90%
1 Year
+48.63%
+48.63%

More News

Read More
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
Via Chartmill
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in December
Via The Motley Fool
Earnings Preview: Exelixis
Via Benzinga
1 No-Brainer Stock to Buy With $40
Via The Motley Fool
Analyst Ratings For Exelixis
Via Benzinga
Navigating 16 Analyst Ratings For Exelixis
Via Benzinga
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis)
Via Talk Markets
Topics Stocks / Equities
Ten Young Ones
Via Talk Markets
Topics Stocks / Equities
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
BioNTech Stock Got A IBD RS Rating Lift
Via Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Via Benzinga
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Momentum Trades For The Q4 Rally
Via Talk Markets
Momentum Has Narrowed Again, Significantly
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.